A Phase 1, Open-Label, Single Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of MEDI0382 in Subjects With Renal Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 May 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cotadutide (Primary)
Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors MedImmune

04 May 2023 Results assessing the pharmacokinetics, safety and immunogenicity of a single dose of cotadutide in individuals with varying degrees of renal impairment, published in the Clinical Pharmacokinetics.
11 Jun 2019 Results assessing pharmacokinetics of MEDI0382 presented at the 79th Annual Scientific Sessions of the American Diabetes Association
30 Apr 2018 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com